Dear Gopal,
My co bro is travelling to US soon (within 15 days or so).
If you can get the injections couriered to him, he can bring it back to India
and I can forward it to your folks.

Let me know.

Can be done...

G...
--- In ALS_India@yahoogroups.com, "gauravjain_80" <gauravjain_80@...> wrote:
>
> Dear Gopal,
>
> glad 2 hear that ur mum is doing fine...
> I was able 2 get Carnitine tabs but nt the injections.
> Sorry about that.
> Let me know if you still need the tabs...
>
> Tc and keep in touch...
>
> G..
>
> --- In ALS_India@yahoogroups.com, Gopala Krishna Gokeda <gokeda@> wrote:
> >
> > Hi Lalit,
> >
> > Please feel free to call me. My phone number is 705-293-0323 and
705-888-1246. My mother is doing very well. I am having hard time getting the
carnitine injections to India. I am still working on them.
> >
> > Gopal
> >
> >
> >
> >
> >
> > --- On Fri, 3/6/09, Lalit Kumar <lalitgupta907@> wrote:
> >
> > From: Lalit Kumar <lalitgupta907@>
> > Subject: Re: [ALS_India] WHY THE NEW GENE FINDINGS ARE A CALL TO ACTION - A
PACKARD PERSPECTIVE
> > To: ALS_India@yahoogroups.com
> > Date: Friday, March 6, 2009, 10:24 PM
> >
> >
> >
> >
> >
> >
> >
> >
> >
> >
> >
> >
> > hello gaurav bhaiya
> > Do you know any thing about gopal's mother...one thing i want to know once
gopal told me about his neighbour in canada that the person was able to cure his
wife from MND by giving injection of l-carnitine. ..Do u know any thing about
this context????? ??Also do u have any phone no 4 contacting him... want to know
about that lady who was able to cure 4m this prob.....can u do any help regardig
this....If gopal got this mail kindly respond me..
> >
> >  
> > thanx
> >  
> > lalit
> >
> >  
> > On 3/5/09, gauravjain_80 <gauravjain_80@ yahoo.com> wrote:
> >
> >
> >
> >
> >
> > WHY THE NEW GENE FINDINGS ARE A CALL TO ACTION - A PACKARD PERSPECTIVE
> > http://www.alscente r.org/news/ briefs/090304. cfm
> >
> >
> > In 2003, when New England ALS scientists announced they'd discovered
> > another form of familial ALS - the sixth one, and an adult form that
> > seems to strike harder in the lower extremities and have a somewhat
> >
> > faster course - the hope was that the gene for it would soon surface.
> >
> > High excitement in the ALS research community always accompanies
> > finding a new gene: Perhaps this one holds clues to reveal what triggers
> >
> > motor neuron death; perhaps this one will spark a really effective
> > therapy.
> >
> > Last week, after a six-year search, the gene was announced by seasoned
> > collaborators at the University of Massachusetts and Massachusetts
> >
> > General Hospital. Another research team at King's College in London
> > backed up the finding. Found where they'd suspected it, on chromosome
> > 16, the mutated FUS gene (for "fused in sarcoma") is responsible for
> >
> > perhaps 5 percent of familial ALS. And pinpointing it, after a long,
> > thorough search, would be news enough.
> >
> > But this discovery appears to go beyond the usual. Packard scientists
> > warmly welcome the appearance of m(for mutated) FUS for a key reason: It
> >
> > lends clout to a theory about a major destructive process in ALS that's
> > been gathering evidence at the Packard Center and elsewhere more than a
> > decade.
> >
> > "The fascinating thing about having the FUS gene linked to ALS," says
> >
> > Packard Scientific Director Piera Pasinelli, "is that it's yet another
> > gene that plays a part in RNA processing."
> >
> > And having successful functioning of that molecule is crucial for cells
> > to work normally. By way of background: RNA - specifically the messenger
> >
> > RNA molecule - carries DNA's blueprint for assembling proteins into the
> > cell cytoplasm where their actual assembly occurs. Yet getting RNA to
> > reflect DNA's "message" accurately, modifying it for efficiency and then
> >
> > transporting it from the cell nucleus to the cytoplasm is an involved,
> > multi-step process. And it's a one that can go awry.
> >
> > In 1998, Packard scientists first published the find that some 65
> > percent ALS patients harbor abnormal messenger RNA molecules,
> >
> > specifically in the injured parts of their central nervous systems. But
> > no one has known the cause of that or what, if any, part it plays in
> > ALS's downhill course.
> >
> > More evidence: Not long ago, Packard researchers helped discover the
> >
> > familial ALS4 gene, one for an abnormal form of a protein called
> > senataxin. Like FUS, the senataxin gene also has an RNA role, overseeing
> > proper production of messenger RNA from its DNA blueprint.
> >
> > And last year, the King's College group showed mutations in yet another
> >
> > gene - one called TDP-43 - that appears both in patients with a variety
> > of different familial ALS types and, amazingly, in sporadic ALS patients
> > as well. Healthy people lack these mutations. (Last week, Packard
> > scientist Wim Robberecht and his European team added to that,
> >
> > discovering a new variation of the TDP-gene in familial ALS patients.)
> > *
> >
> > Among TDP-43's list of accomplishments? RNA processing.
> >
> > All this suggests that flawed RNA metabolism, then, may join ALS's
> >
> > seven "ugly stepsisters," as another of the biological pathways to go
> > wrong in ALS. (In scientific terms, the seven stepsisters are: oxidative
> > damage, misfolded protein aggregates, dysfunctional mitochondria,
> >
> > defects in motor neuron transport, growth factor deficiency, pathology
> > of glial cells, glutamate excitotoxicity. )
> >
> > What has Packard scientists most engaged, however, is where the flawed
> > RNA metabolism could lead. It's interesting, for example, that both
> >
> > patients with ALS from mTDP-43 and those with ALS from mFUS appear to
> > show clumps of misfolded proteins - protein aggregates - in central
> > nervous system cells, early in the disease. "This suggests that these
> >
> > aggregates are key agents, that they participate early in the genesis of
> > ALS," says Packard scientist Phil Wong, who has just made a mouse model
> > of ALS using a mutant TDP-43 gene.
> >
> > So an important next step, both for understanding and for therapy, Wong
> >
> > says, is to "see whether these aggregates are indeed critical players or
> > if, instead, they're just `tombstones' that mark dying motor neurons."
> > His mouse model should help answer that question.
> >
> >
> > In this, the new "stepsister" may be the most useful. Because it shows
> > up in both familial and sporadic patients, some researchers are even
> > speculating that RNA gone awry may be the missing overarching principle
> >
> > that tells how the stepsisters are related. In other words, some are
> > hoping it may be the key process that causes ALS.
> >
> > "The new discoveries, we believe, point strongly to flawed RNA
> > metabolism as a key disease process to imitate in animal models for
> >
> > ALS," says Rothstein.
> >
> > "It's these tools - the gene-primed model mice and fish and fruit flies
> > that Packard scientists offer the world's research community - that will
> > enable us to understand ALS. Ultimately, they'll become the agents we'll
> >
> > all use to find effective therapies."
> >
> > *Robberecht is already busy making a zebrafish model of ALS using
> > mutant TDP-43. His Packard colleague J. Paul Taylor, has begun testing a
> > new TDP-43 fruit fly model.
> >
> >
> > ____________ _________ _________ _____
> >
> > About The Robert Packard Center for ALS Research at Johns Hopkins
> > www.alscenter. org
> >
> >
> > Located in Baltimore, the Robert Packard Center for ALS Research at
> > Johns Hopkins is a worldwide collaboration of scientists aimed at
> > developing therapies and a cure for amyotrophic lateral sclerosis (ALS),
> > also known as Lou Gehrig's disease.
> >
> >
> > The Center is the only institution of its kind dedicated solely to the
> > disease. Its research is meant to translate rapidly from the lab bench
> > to the clinic, largely by eliminating time spent waiting for grants and
> >
> > lowering institutional barriers to sharing scientific results.
> >
> > Scientists and clinician members of the Packard Center have moved drugs
> > reliably and rapidly from preclinical experiments to human trials.
> > Direct or indirect links to international biotech or pharmaceutical
> >
> > companies bring the infrastructure and experience needed to make
> > promising drugs into therapies.
> >
> > Packard scientists are the first to propose and test a combination
> > approach to drug therapy, a tactic that has worked for AIDS, cancer and
> >
> > other diseases.
> >
> > ALS is a progressive, disabling neuromuscular disease that causes
> > complete paralysis and loss of function - including the ability to eat,
> > speak and breathe. ALS progresses quickly and is not curable. Most
> >
> > patients die within five years of diagnosis.
> >
> > ____________ _________ _________ _________ __
> > Rebecca Berger
> > Research Program Coordinator
> > Robert Packard Center for ALS Research at Johns Hopkins
> > 5801 Smith Avenue | McAuley Suite 110
> >
> > Baltimore, MD 21209
> > 410.735.7678 direct
> > 410.735.7680 fax
> > rberger6@jhmi. edu
> > www.alscenter. org
> >
> > www.fiesta5K. org
> >
>